Genprex (GNPX) announced that its research collaborators will present at the upcoming 2025 American Association for Cancer Research, or AACR, ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Weakness in some key brands, like Otezla and Lumakras, creates potential revenue headwinds. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025 due to biosimilar ...

Concurrently, their product developments, such as the positive Phase III results for TEZSPIRE® and FDA approval for LUMAKRAS®, signal strong therapeutic advancements. The announcement of Amgen ...